John DeFord - Becton Dickinson Executive Vice President, Chief Technology Officer
BDX Stock | USD 234.15 0.21 0.09% |
President
Dr. John A. DeFordas is Executive Vice President, Chief Technology Officer of the Company. Since the completion of the C. R. Bard, Inc. transaction, DeFord has served as senior vice president of RD for the Interventional Segment at BD. Prior to the acquisition, he served as senior vice president for Science, Technology and Clinical Affairs at Bard. DeFord joined Bard in 2004 as vice president of Science and Technology after serving as a managing director for life science investments with Early Stage Partners, a VC fund. Prior to Early Stage Partners, DeFord was president and CEO of Cook Inc., now known as Cook Medical. DeFord serves on the board of directors of NuVasive and is a member of the executive faculty at the Krannert School of Management and Weldon School of Biomedical Engineering at Purdue University. He received bachelor and master degrees in electrical engineering and a doctorate in electrical and biomedical engineering from Purdue. DeFord is published in multiple scientific journals, holds numerous patents and was recognized with several industry honors.
Age | 55 |
Address | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 |
Phone | 201 847 6800 |
Web | https://www.bd.com |
Becton Dickinson Management Efficiency
The company has Return on Asset of 0.0312 % which means that on every $100 spent on assets, it made $0.0312 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0513 %, implying that it generated $0.0513 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 53.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 603.1 M in 2024.Similar Executives
Showing other executives | PRESIDENT Age | ||
David Helsel | Haemonetics | 50 | |
David Wilson | Haemonetics | N/A | |
Kim Seabury | AngioDynamics | 57 | |
Tom McCall | ICU Medical | 60 | |
David Montecalvo | West Pharmaceutical Services | 54 | |
Benjamin Davis | AngioDynamics | 60 | |
Christopher Ryan | West Pharmaceutical Services | 63 | |
Virginia Sanzone | ICU Medical | 49 | |
Ben Davis | AngioDynamics | 50 | |
Warwick Bedwell | West Pharmaceutical Services | 55 | |
Eric Resnick | West Pharmaceutical Services | 55 | |
Gary Barrett | AngioDynamics | 46 | |
Silji Abraham | West Pharmaceutical Services | 52 | |
David Helsel | AngioDynamics | 60 | |
Barbara Kucharczyk | AngioDynamics | 43 | |
Michael Anderson | West Pharmaceutical Services | 60 | |
Sandra Jesse | Haemonetics | 62 | |
Chad Campbell | AngioDynamics | 53 | |
Jacqueline Scanlan | Haemonetics | 46 | |
Thomas McCurdy | Haemonetics | N/A | |
Neil Ryding | Haemonetics | 55 |
Management Performance
Return On Equity | 0.0513 | ||||
Return On Asset | 0.0312 |
Becton Dickinson Leadership Team
Elected by the shareholders, the Becton Dickinson's board of directors comprises two types of representatives: Becton Dickinson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Becton. The board's role is to monitor Becton Dickinson's management team and ensure that shareholders' interests are well served. Becton Dickinson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Becton Dickinson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Reidy, Chief Financial Officer, Executive Vice President, Chief Administrative Officer | ||
Denise Fleming, Executive Officer | ||
Ellen Strahlman, Chief Medical Officer, Senior Vice President - Research and Development | ||
Willard Overlock, Independent Director | ||
Rebecca Rimel, Independent Director | ||
Thomas Spoerel, Senior Vice President, Controller and Chief Accounting Officer, Principal Accounting Officer | ||
Gary Cohen, Executive VP | ||
Claire Fraser, Independent Director | ||
Alexandre Conroy, Executive Vice President, Chief Integrated Supply Chain Officer | ||
John Gallagher, VP of Corporate Fin., Treasurer and Controller | ||
Ami Simunovich, Regulatory Quality | ||
James Orr, Independent Director | ||
Monique Dolecki, IR Contact Officer | ||
Jeffrey Henderson, Independent Director | ||
John DeFord, Executive Vice President, Chief Technology Officer | ||
Greg Rodetis, Head Relations | ||
Christopher Jones, Independent Director | ||
Jeffrey Sherman, Senior Vice President General Counsel | ||
Edward DeGraan, Independent Director | ||
Antoinette Segreto, Senior Taxes | ||
Claire Pomeroy, Independent Director | ||
Patrick Kaltenbach, Executive Vice President, President - Life Sciences | ||
Michael Garrison, Executive segment | ||
Catherine Burzik, Independent Director | ||
Nabil Shabshab, Senior Vice President Chief Marketing Officer | ||
Claudia Curtis, Chief VP | ||
Linda Tharby, Segment President — Life Sciences | ||
Charles Bodner, Senior Vice President Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer | ||
R Eckert, Independent Director | ||
William Kozy, COO and Executive VP | ||
Roland Goette, Executive Vice President and Presidentident - EMEA | ||
James Lim, Executive Vice President and President, Greater Asia | ||
Basil Anderson, Independent Director | ||
Antoine Ezell, Executive Vice President and Presidentident, North America and Chief Marketing Officer | ||
Andrew Eckert, Independent Director | ||
Thomas Polen, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer | ||
Marshall Larsen, Lead Independent Director | ||
Troy Kirkpatrick, VP PR | ||
Stephen Sichak, Senior Vice President - Integrated Supply Chain | ||
Alberto Mas, Executive Vice President and President - Life Sciences Segment | ||
William Tozzi, Interim President - Interventional | ||
Michelle Quinn, Executive Counsel | ||
Carla Burigatto, Senior Officer | ||
Shana Neal, Executive Officer | ||
Alfred Sommer, Independent Director | ||
Ching leong, Executive Vice President and President Greater Asia | ||
Elizabeth McCombs, Executive Officer | ||
Bertram Scott, Independent Director | ||
FACC MD, Chief VP | ||
Gary Mecklenburg, Independent Director | ||
Samrat Esq, Public Devel | ||
Henry Becton, Lead Independent Director | ||
Francesca DeMartino, VP Relations | ||
David Hickey, Executive Vice President and President, Life Sciences Segment | ||
Betty Larson, Executive Vice President- Human Resources, Chief Human Resources | ||
James Borzi, Executive Vice President - Global Operations, Chief Supply Chain Officer | ||
William Brown, Independent Director | ||
Simon Campion, Executive Vice President and President BD Interventional Segment | ||
Carrie Byington, Independent Director | ||
Vincent Forlenza, Chairman, CEO and President and Chairman of Executive Committee | ||
Christopher DelOrefice, Chief Financial Officer, Executive Vice President | ||
Jerome Hurwitz, Senior Vice President - Human Resources | ||
Samrat Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel | ||
David Melcher, Independent Director | ||
Timothy Ring, Independent Director |
Becton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Becton Dickinson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0513 | ||||
Return On Asset | 0.0312 | ||||
Profit Margin | 0.06 % | ||||
Operating Margin | 0.11 % | ||||
Current Valuation | 82.5 B | ||||
Shares Outstanding | 288.9 M | ||||
Shares Owned By Insiders | 0.31 % | ||||
Shares Owned By Institutions | 89.33 % | ||||
Number Of Shares Shorted | 2.93 M | ||||
Price To Earning | 45.86 X |
Pair Trading with Becton Dickinson
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Becton Dickinson position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Becton Dickinson will appreciate offsetting losses from the drop in the long position's value.Moving together with Becton Stock
0.63 | CVS | CVS Health Corp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Becton Dickinson could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Becton Dickinson when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Becton Dickinson - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Becton Dickinson and to buy it.
The correlation of Becton Dickinson is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Becton Dickinson moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Becton Dickinson moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Becton Dickinson can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Becton Dickinson and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Becton Dickinson information on this page should be used as a complementary analysis to other Becton Dickinson's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Becton Stock analysis
When running Becton Dickinson's price analysis, check to measure Becton Dickinson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Becton Dickinson is operating at the current time. Most of Becton Dickinson's value examination focuses on studying past and present price action to predict the probability of Becton Dickinson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Becton Dickinson's price. Additionally, you may evaluate how the addition of Becton Dickinson to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Becton Dickinson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Becton Dickinson. If investors know Becton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Becton Dickinson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Dividend Share 3.68 | Earnings Share 4.36 | Revenue Per Share 67.719 | Quarterly Revenue Growth 0.026 |
The market value of Becton Dickinson is measured differently than its book value, which is the value of Becton that is recorded on the company's balance sheet. Investors also form their own opinion of Becton Dickinson's value that differs from its market value or its book value, called intrinsic value, which is Becton Dickinson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Becton Dickinson's market value can be influenced by many factors that don't directly affect Becton Dickinson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Becton Dickinson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Becton Dickinson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Becton Dickinson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.